Skip to Content

PROLOR Biotech To Present Data On Its Long-Acting Clotting Factors At Leading International Scientific Conference

LIVERPOOL, England and NES-ZIONA, Israel, June 29, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that PROLOR scientist Dr. Gili Hart will present data on the company's long-acting clotting factors in preclinical development for the treatment of hemophilia at the 58th Annual Meeting of the Science and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH). Dr. Hart's oral presentation will take place tomorrow, June 30, 2012, at the ISTH meeting in Liverpool, UK.

In her presentation, Dr. Hart will discuss data from preclinical studies of PROLOR's long-acting versions of Factor VIIa (Factor Vlla-CTP) and Factor lX (Factor IX-CTP). Top-line results of these studies were previously reported by PROLOR. The results showed that compared to commercially available Factor VIIa, hemophilic mice receiving Factor VIIa-CTP demonstrated a superior survival rate over a longer time period following a bleeding challenge, superior and longer-lasting generation of the pro-clotting enzyme thrombin, and significantly higher in vivo recovery, a pharmacokinetic measure of clotting activity.

Factor IX-CTP demonstrated significantly longer duration of clotting activity in a hemophilic mice model compared with commercially available Factor IX, and bleeding episodes were significantly shorter and less intense for the group treated with Factor IX-CTP. In addition, none of the animals treated with Factor IX-CTP had any spontaneous re-occurring bleeding events, compared with a 50% incidence of re-bleeding events for the group treated with commercial Factor IX.

PROLOR CEO Dr. Abraham Havron commented, "The ISTH provides critical scientific guidance to researchers and clinicians working to improve the treatment of clotting and thrombotic disorders globally, and we are very pleased that our promising new approaches for managing hemophilia have been selected for presentation at this prestigious meeting."

Dr. Hart's presentation, "A clinically validated technology for elongating the half life of coagulation factors, enabling a prolonged haemostatic activity in hemophilic animal models," is scheduled at 12:10 pm BST on June 30, 2012. The 58th Annual Meeting of the Science and Standardization Committee of the ISTH is being held June 27-30, 2012. For more information, visit

The International Society on Thrombosis and Haemostasis (ISTH) is an international organization whose mission is the advancement of education and stimulation of research into thrombosis and hemostasis through meetings, peer-reviewed publications and expert committees on practical issues related to research methods and standards. The ISTH, with its Scientific and Standardization Committee, also provide expert consultation to national and international regulatory agencies and health organizations. For more information, visit

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development. For more information, visit

Safe Harbor Statement : This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.


Shai Novik, President
Barbara Lindheim

PROLOR Biotech, Inc.
BLL Partners, LLC

Tel: +1 866 644-7811
+1 212 584-2276



Web Site:


Posted: June 2012